Given the increasing success and subsequent interest in cancer immunotherapies, there is a growing need for well-characterized preclinical models to enable drug discovery efforts. Syngeneic mouse tumor models offer advantages over conventional xenograft models for immunotherapy studies because the animals have a functional immune system. Charles River offers a broad range of syngeneic tumor models and has evaluated the responsiveness of several of these models to known immune checkpoint inhibitors anti-CTLA-4 and anti-PD-1. This webinar describes the results of these characterizations, which clearly show a differential response across tumors when these inhibitors were used individually or in combination.


  • Joseph Murphy, PhD, Director of R&D, Science Operations, Oncology